SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nutex Health, Inc. (NUTX) trades at a trailing P/E of 10.7, forward P/E of 7.0. Trailing earnings yield is 9.37%, forward earnings yield 14.29%. PEG 4.45. Graham Number is $116.71.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (10.7); analyst target implies upside (+90.1%); earnings yield beats bond yields (9.37%).
- Forward P/E 7.0 (down from trailing 10.7) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 4.45 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 9.37% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 14.29% as earnings recover.
- Analyst consensus target $205.00 (+90.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 77/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NUTX
Valuation Multiples
P/E (TTM)10.7
Forward P/E7.0
PEG Ratio4.45
Forward PEG0.15
P/B Ratio2.08
P/S Ratio0.70
EV/EBITDA2.8
Per Share Data
EPS (TTM)$9.58
Forward EPS (Est.)$15.41
Book Value / Share$63.19
Revenue / Share$130.61
FCF / Share$36.65
Yields & Fair Value
Earnings Yield9.37%
Forward Earnings Yield14.29%
Dividend Yield0.00%
Graham Number$116.71
SharesGrow IV$538.09 (+399%)
Analyst Target$205.00 (+90.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-1,667.9 |
0.19 |
-2,111.96 |
0.00 |
- |
| 2017 |
43,124.8 |
-415.11 |
10,595.85 |
467,897.78 |
- |
| 2018 |
-15,316.8 |
40.46 |
-28,787.61 |
471,750.06 |
- |
| 2019 |
1,187.1 |
-1.06 |
877.36 |
255.91 |
0.08% |
| 2020 |
243.0 |
0.47 |
300.09 |
93.97 |
0.23% |
| 2021 |
181.8 |
5.07 |
210.27 |
72.72 |
0.60% |
| 2022 |
-2.8 |
0.01 |
12.57 |
5.49 |
4.25% |
| 2023 |
-2.6 |
0.03 |
1.94 |
0.48 |
4.38% |
| 2024 |
3.1 |
-0.02 |
1.10 |
0.34 |
3.98% |
| 2025 |
15.6 |
1.77 |
3.35 |
1.26 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-3.60 |
$0.00 |
$-7.43M |
- |
| 2017 |
$0.14 |
$53.65K |
$582.06K |
1085% |
| 2018 |
$-0.39 |
$91.37K |
$-2.81M |
-3080% |
| 2019 |
$3.98 |
$97.06M |
$16.48M |
17% |
| 2020 |
$24.69 |
$273.42M |
$105.97M |
38.8% |
| 2021 |
$33.55 |
$331.53M |
$132.59M |
40% |
| 2022 |
$-102.24 |
$219.29M |
$-432.74M |
-197.3% |
| 2023 |
$-10.39 |
$247.65M |
$-45.79M |
-18.5% |
| 2024 |
$10.23 |
$479.95M |
$52.18M |
10.9% |
| 2025 |
$10.48 |
$875.26M |
$70.79M |
8.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$15.41 |
$14.74 – $16.35 |
$910.48M |
$856.14M – $989.61M |
1 |
| 2027 |
$17.56 |
$16.79 – $18.62 |
$947.42M |
$939.63M – $955.2M |
1 |
